Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Sernova Corp. (OTCQB: SEOVF) and Evotec SE have announced a strategic partnership to develop an off-the-shelf cell replacement therapy for insulin-dependent diabetes. The collaboration leverages Sernova's Cell Pouch System with Evotec's iPSC-based insulin-producing beta cells. Evotec will invest CAD $27 million in Sernova, enhancing the partnership aimed at providing a scalable solution for diabetes treatment. Both companies will fund preclinical development together, with Sernova acquiring options for exclusive licensing of Evotec's beta cells.